Synthetic cannabinoid use disorder is emerging as a significant clinical issue. This article provides the general psychiatrist with an overview of the physical and psychiatric adverse effects of chronic synthetic cannabinoid use, as well as specific clinical responses.
Method:
We performed electronic searches of Ovid MEDLINE and Ovid Embase to identify key articles, of all methodological designs, published up to June 2018.
Results:
The available evidence suggests that, compared to cannabis, use of synthetic cannabinoids is associated with the more rapid development of dependence, increased psychiatric risks and complex withdrawal, and serious physical adverse effects that include seizures, cardiotoxicity and death, denoting a potential need for more intensive management.
Conclusion:
When synthetic cannabinoid use is identified, along with management of acute physical and psychiatric adverse effects, psychotherapeutic strategies to reduce use and/or harm are recommended.
RechMADonaheyECappiello DziedzicJM, et al. New drugs of abuse. Pharmacotherapy2015; 35: 189–197.
2.
ClancyRVHodgsonRCKendurkarA, et al. Synthetic cannabinoid use in an acute psychiatric inpatient unit. Int J Ment Health Nurs2018; 27: 600–607.
3.
Van HoutMCHearneE. User experiences of development of dependence on the synthetic cannabinoids, 5f-AKB48 and 5F-PB-22, and subsequent withdrawal syndromes. Int J Ment Health Addiction2017; 15: 565–579.
4.
FantegrossiWEMoranJHRadominska-PandyaA, et al. Distinct pharmacology and metabolism of K2 synthetic cannabinoids compared to Δ 9-THC: mechanism underlying greater toxicity?Life Sci2014; 97: 45–54.
IbrahimSAl-SaffarFWannenburgT.A unique case of cardiac arrest following K2 abuse. Case Rep Cardiol2014; 2014: Article ID 120607. https://doi.org/10.1155/2014/120607.
7.
BrightSJBishopBKaneR, et al. Kronic hysteria: exploring the intersection between Australian synthetic cannabis legislation, the media, and drug-related harm. Int J Drug Pol2013; 24: 231–237.
8.
KronstrandRRomanMAnderssonM, et al. Toxicological findings of synthetic cannabinoids in recreational users. J Anal Toxicol2013; 37: 534–541.
9.
BehonickGShanksKGFirchauDJ, et al. Four postmortem case reports with quantitative detection of the synthetic cannabinoid, 5F-PB-22. J Anal Toxicol2014; 38: 559–562.
10.
BronsteinACSpykerDACantilenaLRJr, et al. 2011 annual report of the American Association of Poison Control Centers’ National Poison data system (NPDS): 29th annual report. Abingdon: Taylor & Francis, 2012.
11.
HoyteCOJacobJMonteAA, et al. A characterization of synthetic cannabinoid exposures reported to the National Poison Data System in 2010. Ann Emerg Med2012; 60: 435–438.
12.
BonarEEAshrafiounLIlgenMA.Synthetic cannabinoid use among patients in residential substance use disorder treatment: prevalence, motives, and correlates. Drug Alcohol Depend2014; 143: 268–271.
13.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5®). Washington, DC: American Psychiatric Association, 2013.
14.
BarrattMJCakicVLentonS.Patterns of synthetic cannabinoid use in Australia. Drug Alcohol Rev2013; 32: 141–146.
MacfarlaneVChristieG.Synthetic cannabinoid withdrawal: a new demand on detoxification services. Drug Alcohol Rev2015; 34: 147–153.
17.
CooperZD.Adverse effects of synthetic cannabinoids: management of acute toxicity and withdrawal. Curr Psychiatr Rep2016; 18: 52.
18.
ZimmermannUSWinkelmannPRPilhatschM, et al. Withdrawal phenomena and dependence syndrome after the consumption of “spice gold”. Deutsches Ärzteblatt International2009; 106: 464.
19.
NaccaNVattiDSullivanR, et al. The synthetic cannabinoid withdrawal syndrome. J Addiction Med2013; 7: 296–298.
20.
RomingerACummingPXiongG, et al. Effects of acute detoxification of the herbal blend ‘Spice Gold’on dopamine D 2/3 receptor availability: a [18 F] fallypride PET study. Eur Neuropsychopharmacol2013; 23: 1606–1610.
21.
AllsopDJNorbergMMCopelandJ, et al. The Cannabis Withdrawal Scale development: patterns and predictors of cannabis withdrawal and distress. Drug Alcohol Depend2011; 119: 123–129.
22.
PapantiDSchifanoFBotteonG, et al. “Spiceophrenia”: a systematic overview of “Spice”-related psychopathological issues and a case report. Hum Psychopharmacol Clin Exp2013; 28: 379–389.
23.
HurstDLoefflerGMcLayR.Psychosis associated with synthetic cannabinoid agonists: a case series. Am J Psychiatr2011; 168: 1119.
24.
Every-PalmerS.Synthetic cannabinoid JWH-018 and psychosis: an explorative study. Drug Alcohol Depend2011; 117: 152–157.
25.
FattoreL.Synthetic cannabinoids—further evidence supporting the relationship between cannabinoids and psychosis. Biol Psychiatr2016; 79: 539–548.
26.
EnglundAMorrisonPDNottageJ, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol2013; 27: 19–27.
27.
ForresterMBKleinschmidtKSchwarzE, et al. Synthetic cannabinoid and marijuana exposures reported to poison centers. Hum Exp Toxicol2012; 31: 1006–1011.
28.
LubmanDICheethamAYücelM.Cannabis and adolescent brain development. Pharmacol Therapeut2015; 148: 1–16.
29.
MorrisonPZoisVMcKeownD, et al. The acute effects of synthetic intravenous Δ9-tetrahydrocannabinol on psychosis, mood and cognitive functioning. Psychol Med2009; 39: 1607–1616.
30.
Van LaarMVan DorsselaerSMonshouwerK, et al. Does cannabis use predict the first incidence of mood and anxiety disorders in the adult population?Addiction2007; 102: 1251–1260.
31.
VinodKYHungundBL.Role of the endocannabinoid system in depression and suicide. Trends Pharmacol Sci2006; 27: 539–545.
32.
ViverosMMarcoEM.File SE, endocannabinoid system and stress and anxiety responses. Pharmacol Biochem Behav2005; 81: 331–342.
33.
TaiSFantegrossiWE. Pharmacological and toxicological effects of synthetic cannabinoids and their metabolites. In: BaumannMHGlennonRAWileyJL (eds) Neuropharmacology of New Psychoactive Substances (NPS): The Science Behind the Headlines. Cham, Switzerland Springer, 2016, pp. 249–262.
